Frovatriptan

Exposed non-exposed studies (cohort)

Study Country
Study period
Population source Exposure definition Non-exposure definition Sample size Rmk
Spielmann (Control mainly exposed other treatments, sick), 2017 Germany
1999 - 2014
Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy. Pregnant women with Frovatriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study). exposed to other treatment, sick
Pregnant women suffering from migraine disorder but not taking triptans between their last menstrual period and delivery.
19 / 475 The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
Spielmann (Control unexposed, disease free), 2017 Germany
1999 - 2014
Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy. Pregnant women with Frovatriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study). unexposed, disease free
Pregnant women without migraine disorder who were neither exposed to triptans nor to one of the following established teratogens or fetotoxicant.
19 / 1733 The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.

Case-control studies (cohort)

Study Country
Study period
Case Control Sample size Rmk

See the method used to produce these results